{"url_path":"/sec/mira/8-k/2026-07-06/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-06","source_url":"https://www.sec.gov/Archives/edgar/data/1904286/0001493152-26-032091-index.html","accession_number":"0001493152-26-032091","cik":"0001904286","ticker":"MIRA","issuer_name":"MIRA PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1904286/0001493152-26-032091-index.html","primary_entity_key":"0001904286","primary_entity_name":"MIRA PHARMACEUTICALS, INC."},"word_count":260,"has_tables":true,"body_markdown":"**Item\n7.01 Regulation FD Disclosure.**\n\n \n\nOn\nJuly 6, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) issued a press release announcing positive results from preclinical\nstudies evaluating the optimized oral formulation of SKNY-1, the Company’s oral drug candidate being developed for obesity and\naddiction-related disorders.\n\n \n\nThe\nstudies demonstrated favorable oral bioavailability together with reproducible systemic exposure and robust brain penetration, and substantial\nliver exposure following oral administration. Peak plasma concentrations and kinetics supported the potential for convenient once-daily\noral dosing.\n\n \n\nThe\nCompany believes these pharmacokinetic findings further strengthen the development profile of SKNY-1 by demonstrating that the optimized\noral formulation delivers meaningful systemic exposure together with distribution into pharmacologically relevant tissues. These findings\ncomplement the Company’s previously reported preclinical efficacy and behavioral studies demonstrating significant reductions in\nbody weight, preservation of lean body mass, improvements in metabolic parameters, attenuation of compulsive feeding and nicotine-seeking\nbehaviors, and evidence that SKNY-1 did not produce anxiety-related behavioral effects in a validated preclinical\nmodel despite demonstrated cannabinoid receptor activity.\n\n \n\nA\ncopy of the Company’s press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.\n\n \n\nThe\ninformation contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes\nof Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities\nof that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the\nExchange Act, except as expressly set forth by specific reference in such filing."}